NASDAQ:REVB Revelation Biosciences (REVB) Stock Price, News & Analysis $0.90 -0.01 (-1.10%) (As of 09/13/2024 ET) Add Compare Share Share Today's Range$0.86▼$0.9250-Day Range$0.85▼$2.0952-Week Range$0.81▼$25.26Volume144,672 shsAverage Volume928,933 shsMarket Capitalization$1.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Revelation Biosciences alerts: Email Address Revelation Biosciences MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy7.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($12.46) to ($6.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.12 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Revelation Biosciences.Read more about Revelation Biosciences' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted7.34% of the float of Revelation Biosciences has been sold short.Short Interest Ratio / Days to CoverRevelation Biosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Revelation Biosciences has recently decreased by 61.62%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRevelation Biosciences does not currently pay a dividend.Dividend GrowthRevelation Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for REVB. Previous Next 4.1 News and Social Media Coverage News SentimentRevelation Biosciences has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Revelation Biosciences this week, compared to 0 articles on an average week.Search Interest14 people have searched for REVB on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Revelation Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Revelation Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.22% of the stock of Revelation Biosciences is held by insiders.Percentage Held by InstitutionsOnly 12.80% of the stock of Revelation Biosciences is held by institutions.Read more about Revelation Biosciences' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Revelation Biosciences are expected to grow in the coming year, from ($12.46) to ($6.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revelation Biosciences is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Revelation Biosciences is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRevelation Biosciences has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Revelation Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThis Crypto Coin Could 10x FASTER Than BitcoinA shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move is being made in preparation to onboard all of Sony products (including Sony's Playstation, which captured a record 62% share of the global gaming console market in 2024). Enthusiasts and experts are buzzing with anticipation qnd one little-known crypto coin is poised for RAPID growth as we see this all unfold.Click here to review my research and unique strategy to score potential profits from this under-the- About Revelation Biosciences Stock (NASDAQ:REVB)Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.Read More REVB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REVB Stock News HeadlinesSeptember 3, 2024 | msn.comRevelation Biosciences files for secondary offering of about 5.1M sharesAugust 22, 2024 | ca.finance.yahoo.comRevelation Biosciences, Inc. (REVBW)September 13, 2024 | Porter & Company (Ad)War on Elon Escalates… Elon Musk just built a supercomputer in Memphis, Tennessee. It took him only 122 days. Dubbed “Colossus,” this supercomputer aims to become the most powerful AI training system in the world. Housed in a 785,000 sq. ft facility in Memphis, Colossus will soon require 150 megawatts of electricity per day. That’s about equal to the amount of energy needed to power 100,000 homes per year. August 21, 2024 | benzinga.comRevelation Biosciences (NASDAQ:REVB) Stock, Short Interest ReportAugust 21, 2024 | benzinga.comRevelation Biosciences (NASDAQ:REVB) Stock Quotes, Forecast and News SummaryAugust 21, 2024 | finance.yahoo.comRevelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross ProceedsAugust 12, 2024 | finance.yahoo.comREVB: Bolsters Cash Amid Positive Trial ResultsAugust 9, 2024 | businesswire.comRevelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024September 13, 2024 | Porter & Company (Ad)War on Elon Escalates… Elon Musk just built a supercomputer in Memphis, Tennessee. It took him only 122 days. Dubbed “Colossus,” this supercomputer aims to become the most powerful AI training system in the world. Housed in a 785,000 sq. ft facility in Memphis, Colossus will soon require 150 megawatts of electricity per day. That’s about equal to the amount of energy needed to power 100,000 homes per year. June 24, 2024 | businesswire.comRevelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker ActivityJune 13, 2024 | businesswire.comRevelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of GeminiMay 10, 2024 | investorplace.comREVB Stock Earnings: Revelation Biosciences Misses EPS for Q1 2024May 10, 2024 | businesswire.comRevelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024March 22, 2024 | businesswire.comRevelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023March 13, 2024 | finance.yahoo.comRevelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)March 4, 2024 | finance.yahoo.comRevelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of GeminiFebruary 13, 2024 | finance.yahoo.comRevelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)February 9, 2024 | msn.comRevelation Biosciences Secures $6.2M in Public OfferingSee More Headlines Receive REVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revelation Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2024Today9/13/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:REVB CUSIPN/A CIK1810560 Webwww.revbiosciences.com Phone650-800-3717FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($30.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-152.41% Return on Assets-74.43% Debt Debt-to-Equity RatioN/A Current Ratio1.10 Quick Ratio1.10 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$25.13 per share Price / Book0.04Miscellaneous Outstanding Shares1,633,000Free Float1,629,000Market Cap$1.45 million OptionableNot Optionable Beta0.19 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. James M. Rolke (Age 55)CEO & Director Comp: $649.25kMr. Chester Stanley Zygmont III (Age 44)CFO & Corporate Secretary Comp: $479.14kMs. Sandra VedrickVice President of Human Resources & Investor RelationsMs. Carol OdleSenior Director of Clinical ProjectsKey CompetitorsElevai LabsNASDAQ:ELABBright Minds BiosciencesNASDAQ:DRUGTitan PharmaceuticalsNASDAQ:TTNPIM CannabisNASDAQ:IMCCBionomicsNASDAQ:BNOXView All CompetitorsInsidersGeorge F. TidmarshSold 925 sharesTotal: $14,430.00 ($15.60/share)George F TidmarshSold 365 sharesTotal: $7,227.00 ($19.80/share)George F TidmarshSold 47 sharesTotal: $972.90 ($20.70/share)George F TidmarshSold 133 sharesTotal: $2,952.60 ($22.20/share)George F TidmarshSold 400 sharesTotal: $9,000.00 ($22.50/share)View All Insider Transactions REVB Stock Analysis - Frequently Asked Questions How have REVB shares performed this year? Revelation Biosciences' stock was trading at $15.0210 at the start of the year. Since then, REVB stock has decreased by 94.0% and is now trading at $0.8990. View the best growth stocks for 2024 here. How were Revelation Biosciences' earnings last quarter? Revelation Biosciences, Inc. (NASDAQ:REVB) announced its quarterly earnings data on Friday, August, 9th. The company reported ($1.54) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.81) by $0.27. When did Revelation Biosciences' stock split? Revelation Biosciences's stock reverse split before market open on Thursday, January 25th 2024. The 1-30 reverse split was announced on Thursday, January 25th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Revelation Biosciences? Shares of REVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:REVB) was last updated on 9/13/2024 by MarketBeat.com Staff From Our Partners44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredPlace this $0.99 trade BEFORE the electionEarlier this year, Millionaire Trader Nate Bear of Monument Traders Alliance went live in front of thousands o...Monument Traders Alliance | Sponsored Turn Smartphones Into “Earnphones”?High-Growth Smartphone Startup 45 Million Users. $60M+ in Revenue. 32,481% Growth Rate. $1T+ market opportu...Mode Mobile | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredKamala Harris To Tank the Market?URGENT ELECTION MELTDOWN WARNING From the former CIA advisor who predicted President Trump’s win in 2016…Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revelation Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revelation Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free REVB Stock Alerts